Xoma

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Bradley Sitko

Chief Investment Officer, Investments

3 past transactions

Pulmokine

Acquisition in 2024
Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine. The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer.

Dare Bioscience

Post in 2024
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Kinnate Biopharma

Acquisition in 2024
Kinnate Biopharma Inc. is a biopharmaceutical company based in San Diego, California, focused on developing small molecule kinase inhibitors for the treatment of genomically defined cancers. Founded in 2018, the company aims to create precision oncology therapeutics to address the needs of underserved patient populations. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is working on KIN003, which targets specific alterations in the FGFR2 and FGFR3 genes, and has other small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor. Kinnate Biopharma employs expertise in structure-based drug discovery and translational research to advance its pipeline of candidates aimed at treating cancers associated with specific oncogenic alterations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.